People

Services

Industries

Firm

About

Knowledge

Careers

News

Events

Contact

Connect

Privacy Policy

Disclaimer

Terms of Use

Accessibility

Payments

Legal

Calgary

Toronto

Edmonton

Ottawa

Vancouver

New York

Montréal

Michael A. Eizenga L.S.M.

Leading Canadian Class Action Litigator at Bennett Jones Toronto

Partner 

William A. Bortolin

Commercial Litigation Lawyer at Bennett Jones Toronto

Associate

Mehak Kawatra

Michael Eizenga L.S.M., William Bortolin and Mehak Kawatra co-author the second chapter of the 2023 edition of the <a rel="noopener noreferrer" rel="noopener noreferrer" href="https://store.thomsonreuters.ca/en-ca/products/annual-review-of-civil-litigation---2023-42979724" target="_blank">Annual Review of Civil Litigation</a>. Their chapter, titled "Proportionality in Pleadings Motions: Applying The Hyrniak Culture Shift to the Assessment of Novel Claims," discusses the impact of the Supreme Court of Canada's decision in Hryniak v. Mauldin on civil litigation, particularly regarding the proportionality principle.

Annual Review of Civil Litigation 2023

Robert W. Staley

Securities & Commercial Litigation Lawyer | Shareholder Disputes

Vice Chair and Partner

Jonathan G. Bell

Commercial, Securities and Class Action Litigation Lawyer at Bennett Jones Toronto

Partner

Fraud Judgment Awarded Against Former Sino Forest CEO

US$2.6-Billion Fraud Judgment Awarded Against Former Sino-Forest CEO

Dominique T. Hussey

Chief Executive Officer and Intellectual Property Litigator, Pharma/Biotech and Trademark Lawyer at Bennett Jones Toronto

Chief Executive Officer

Dominique Hussey and Will Bortolin co-authored Chapter 12 "Stepping into the Hot Tub: Concurrent Expert Evidence in Commercial Arbitration" in "A Practitioner's Guide to Commercial Arbitration". 

A Practitioners Guide to Commercial Arbitration 2017

A Practitioner's Guide to Commercial Arbitration 2017

Shoot to Kill Expert Bias is an Issue of Admissibility

Shoot to Kill: Expert Bias is an Issue of Admissibility – Wise v. Abbott Laboratories, Limited (Part 1)

Serge Dupont

Senior Advisor at Bennett Jones Ottawa

Senior Advisor

Policy and business leaders in 2026 are confronting disruptive global forces that pose daunting economic and financial risks while also transforming markets and creating avenues for growth over the next years.

Economic Outlook Mid Year 2026

A Changing World: New Risks, New Opportunities

2026 Mid-Year Economic Outlook

Alison G. FitzGerald

International Arbitration Lawyer at Bennett Jones Ottawa

Nasra Moumin

Global trade policy is rapidly reshaping the regulatory and commercial landscape for life sciences companies. This update explores how evolving US tariff measures, national security reviews, CUSMA renewal uncertainty and expanding export controls are affecting pharmaceutical and medical device manufacturers operating across borders. The authors also examine Canada&rsquo;s response and the growing compliance, supply chain and market access challenges facing the sector in 2026 and beyond.

The Impact of Global Trade on the Life Sciences Sector

Vincent M. de Grandpré

IP Lawyer | Life Sciences & Tech

Melissa M. Dimilta

Intellectual Property Lawyer at Bennett Jones Toronto

Partner, Trademark Agent

As part of a deeply interconnected global sector, the life sciences industry in Canada is undergoing significant change alongside broad macroeconomic and geopolitical shifts.&nbsp;The Bennett Jones Life Sciences team looks at the top issues and developments affecting the industry in 2026.

2026 Life Sciences outlook

Legal and Market Trends to Watch This Year

Life Sciences Outlook 2026

Emily P. Kettel

Cross-border collaborations are central to the life sciences industry, but they can also raise complex questions about patent infringement liability in Canada. This update examines the Federal Court&rsquo;s recent decision in Adeia Guides Inc v Videotron Ltd and its implications for companies involved in the development, supply and commercialization of patented products and services. The authors explore how Canadian law approaches common design infringement, experimental use exemptions and the potential liability of foreign partners whose activities contribute to products ultimately sold in Canada.

Life Sciences Collaborations and the Risk of Joint Patent Infringement

Aaron E. Sonshine

Corporate Finance, Mergers and Acquisitions and Corporate Governance Lawyer at Bennett Jones Toronto

The life sciences sector is experiencing a renewed wave of M&amp;A activity driven by patent expiries, expanding investor appetite and growing demand for innovative therapies and technologies. Drawing on insights shared at the Bloom Burton &amp; Co. Healthcare Investor Conference, this update explores the key trends shaping dealmaking in Canada and globally, including increased competition for assets, rising private transactions and growing investment in emerging markets such as China. The author also examines why current market conditions point to continued momentum across the sector in the second half of 2026.

Revising Canada's Ethical Rules for Judges Returning to Practice

From the Same Authors